Optimizing the care of patients with advanced prostate cancer in the UK: Current challenges and future opportunities

BJU International

Volumn 110, Issue 5, 2012, Pages 658-667

  Payne, Heather ^a   Bahl, Amit ^b   Mason, Malcolm ^c   Troup, Janis ^d   De Bono, Johann ^e  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d British Uro oncology Group   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

abiraterone acetate; cabazitaxel; chemotherapy; MDV3100; metastatic castration resistant prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; BEVACIZUMAB; CABAZITAXEL; CANCER VACCINE; CARBOPLATIN; CUSTIRSEN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; HYBRID PROTEIN; IPILIMUMAB; MITOXANTRONE; PA 2024; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; UNCLASSIFIED DRUG; ZIBOTENTAN;

ADVANCED CANCER; AGE; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; DRUG COST; DRUG RESPONSE; HEALTH SURVEY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; ONCOLOGIST; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RETREATMENT; SOLID TUMOR; UNITED KINGDOM;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; FORECASTING; HUMANS; MALE; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; PYRROLIDINES; QUESTIONNAIRES; RECOMBINANT FUSION PROTEINS; RETREATMENT; TAXOIDS; THERAPIES, INVESTIGATIONAL; THIONUCLEOTIDES; TISSUE EXTRACTS; UROLOGY;

EID: 84865336863     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10886.x     Document Type: Article

References (54)

1. Heidenreich A, Bolla M, Joniau S, et al. EAU Guidelines on Prostate Cancer. 2010. Available at: http://www.uroweb.org/gls/pdf/ Prostate%20Cancer%202010%20June%2017th.pdf. Accessed September 2010
2. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
3. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI,. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-7
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
5. N.I.C.E. Prostate Cancer: Diagnosis and Treatment. 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf. Accessed September 2010
6. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF,. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-53
7. Hahn NM, Zon RT, Yu M, et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol 2009; 20: 1971-6
8. Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009; 20: 703-8
9. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8
10. Cozar Olmo JM, Carballido Rodriguez J, Luque Galvez P, et al. [Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer]. Actas Urol Esp 2008; 32: 492-501
11. Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054-9 (Pubitemid 41587160)
12. Saad F,. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005; 4: 31-7 (Pubitemid 41018180)
13. Saad F, Chen YM, Gleason DM, Chin J,. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007; 5: 390-6 (Pubitemid 47591666)
14. Saad F, Eastham J,. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010; 76: 1175-81
15. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
16. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82 (Pubitemid 38807610)
17. Payne HA, Gillatt DA,. Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 2007; 99: 545-53 (Pubitemid 46238826)
18. Fowler JE Jr, Whitmore WF Jr,. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982; 49: 1373-7 (Pubitemid 12143058)
19. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
20. Jevtana. Jevtana (cabazitaxel) prescribing information. 2010. Available at: http://products.sanofi-aventis.us/jevtana/jevtana.pdf. Accessed February 2011
21. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
22. EMA. European Medicines Agency Committee for medicinal products for human use (CHMP) Summary of Opionion for Jevtana. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/ human/002018/WC500101045.pdf. Accessed January 2011.
23. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN,. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70: 983-1000
24. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8
25. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501
26. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95
27. Ryan CJ, Efstanthiou E, Smith MR, et al. Abiraterone acetate plus prednisone in chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: results of a multicenter phase II study. Presented at ASCO 2009 Genitourinary Cancers Symposium (abstract 159)
28. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone acetate and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
29. FDA. US Food and drug administration: Abiraterone Acetate. Available at: http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobaccoCDER/ucm253139.htm. Accessed April 2011
30. EMA. European Medicines Agency Committee for medicinal products for human use (CHMP) summary of opinion for Zytiga (abiraterone). 2011. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002321/WC500109205.pdf
31. Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer (NCT00887198). Available at: http://clinicaltrials.gov/ct2/show/NCT00887198?term=abiraterone&cond= prostate+cancer&phase=2&rank=1. Accessed February 2011
32. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
33. Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) (NCT00974311). Available at: http://clinicaltrials.gov/ct2/show/NCT00974311?term=MDV3100&cond= prostate+cancer&phase=2&rank=2. Accessed February 2011
34. A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) (NCT01212991). Available at: http://clinicaltrials.gov/ct2/show/NCT01212991?term= NCT00974311&rank=1. Accessed February 2011
35. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23
36. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int 2010; 106: 966-73
37. Results of Zibotentan phase III trial in castration resistant prostate cancer. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/ Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-pr. Accessed September 2010
38. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate can. Available at: http://www.astrazeneca.com/Media/ Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN. Accessed February 2011
39. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089-94
40. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-6
41. Picus J, Halabi S, Kelly WK, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011; 117: 526-33
42. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28: 18s (Suppl. Abstr. LBA4511)
43. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54
44. Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY) (NCT01188187). Available at: http://clinicaltrials.gov/ct2/show/NCT01188187?term=OGX-011&cond= prostate+cancer&phase=2&rank=1. Accessed February 2011
45. A Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC) (NCT01083615). Available at: http://clinicaltrials.gov/ ct2/show/NCT01083615?term=OGX-011&cond=prostate+cancer&phase=2&rank= 2. Accessed February 2011
46. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan K, Fumoleau P,. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008; 26: (abstract 3599)
47. Coleman RL, Kamat A, Iyer R, et al. Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol 2009; 27: 15s (abstract 5549)
48. Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE) (NCT00519285). Available at: http://clinicaltrials.gov/ct2/show/NCT00519285?term=aflibercept&cond= prostate+cancer&rank=1. Accessed February 2011
49. Provenge (sipuleucel-T) prescribing information. 2010. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/UCM210031.pdf. Accessed February 2011
50. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9
51. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
52. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94 (Pubitemid 46638945)
53. UK Medicines information: New Drugs Online Report for sipuleucel-T. 2011. Available at: http://www.ukmi.nhs.uk/applications/ndo/record-view-open.asp? newDrugID=4048. Accessed February 2011
54. Fierce Biotech: Dendreon (Provenge) to cost $93K for full course of treatment. 2010. Available at: http://www.fiercebiotech.com/story/dendreon- provenge-cost-93k-full-course-treatment/2010-04-29. Accessed March 2011